The investigational therapy bb2121, a possible treatment for relapsed or refractory multiple myeloma patients, is advancing in clinical testing under a recently announced partnership…
Myeloma
A new Phase 3 clinical trial called ACCoRd is underway to investigate the benefits of adding Ninlaro (ixazomib) – a proteasome inhibitor – to…
AbbVie and the International Myeloma Foundation are collaborating to study the role of a genetic mutation — the t(11;14) translocation — in multiple myeloma treatments…
SELLAS Life Sciences’  Galinpepimut-S vaccine more than doubles the time it takes for high-risk multiple myeloma patients’ cancer to worsen, a Phase 2 clinical trial shows.
The supervised use of medicinal cannabis is safe and effective at relieving pain and reducing chemotherapy-induced nausea and vomiting in cancer patients, an increasing body of…
Multiple myeloma patients who failed prior Revlimid (lenalidomide) treatment may benefit from a triple oral combo treatment with Ninlaro (ixazomib), Pomalyst (pomalidomide) and dexamethasone, the results…
A new clinical trial will determine if an exercise program before an autologous stem cell transplant can improve treatment-related side effects in multiple myeloma patients. The…
Seattle Genetics‘ investigational therapy SGN-CD48A, being evaluated in a Phase 1 clinical trial for relapsed or refractory multiple myeloma, was successfully delivered…
Patients with a condition called monoclonal gammopathy of undetermined significance, characterized by the presence of the abnormal monoclonal or M protein, have a small but…
A Phase 1/2 clinical trial testing an experimental T-cell therapy for the first time in human patients will begin in the coming weeks after receiving…
